Moderna Inc [NASDAQ: MRNA] closed the trading session at $57.31.
The stocks have a year to date performance of -42.37 percent and weekly performance of -1.85 percent. The stock has been moved at -44.78 percent over the last six months. The stock has performed -17.15 percent around the most recent 30 days and changed -53.80 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 4.75M shares, MRNA reached to a volume of 4080146 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Moderna Inc [MRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $97.94 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.62. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Moderna Inc shares, keeping their opinion on the stock as Perform, with their previous recommendation back on September 13, 2024. While these analysts kept the previous recommendation, JP Morgan dropped their target price from $88 to $70. The new note on the price target was released on September 13, 2024, representing the official price target for Moderna Inc stock. Previously, the target price had yet another drop from $120 to $65, while Jefferies kept a Hold rating on MRNA stock.
The Average True Range (ATR) for Moderna Inc is set at 2.82, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 4.37. The Price to Book ratio for the last quarter was 1.88, with the Price to Cash per share for the same quarter was set at 22.08.
MRNA stock trade performance evaluation
Moderna Inc [MRNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.85. With this latest performance, MRNA shares dropped by -17.15% in over the last four-week period, additionally sinking by -44.78% over the last 6 months – not to mention a drop of -41.70% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 28.51, with the RSI for the last a single of trading hit 27.83, and the three-weeks RSI is set at 29.46 for Moderna Inc [MRNA]. The present Moving Average for the last 50 days of trading for this stock 72.53, while it was recorded at 57.80 for the last single week of trading, and 103.76 for the last 200 days.
Moderna Inc [MRNA]: An insightful look at the core fundamentals
Moderna Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.92 and a Current Ratio set at 4.09.
Earnings per share (EPS) analysis for Moderna Inc [MRNA] stock
With the latest financial reports released by the company, Moderna Inc posted -9.53/share EPS, while the average EPS was predicted by analysts to be reported at -1.93/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -7.6. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA.
Moderna Inc [MRNA]: Institutional Ownership
There are presently around $72.71%, or 80.36%% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 43.45 million shares, which is approximately 11.3741%. VANGUARD GROUP INC, holding 39.56 million shares of the stock with an approximate value of $$4.7 billion in MRNA stocks shares; and VANGUARD GROUP INC, currently with $$3.04 billion in MRNA stock with ownership which is approximately 6.6917%.
